Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20156264 | 0.95 | PTGER4 (0.37) | CYP11B1CYP11B2CHEK1PTGER4TNKS2 | |
| SCHEMBL20150349 | 0.92 | CYP11B1 (0.35) | CYP11B1CYP11B2CHEK1PTGER4GRM2 | |
| SCHEMBL20150394 | 0.89 | CHEK1 (0.34) | CYP11B1CYP11B2CHEK1PTGER4GRM2 | |
| SCHEMBL20150412 | 0.89 | CASP3 (0.35) | CYP11B1CYP11B2CHEK1PTGER4GRM2 | |
| SCHEMBL20150393 | 0.88 | CYP11B1 (0.37) | CYP11B1CYP11B2CHEK1GRM2CRHR1 | |
| SCHEMBL20150391 | 0.88 | CHEK1 (0.36) | CYP11B1CYP11B2CHEK1PTGER4GRM2 | |
| SCHEMBL20114587 | 0.88 | CHEK1 (0.40) | CYP11B1CYP11B2CHEK1PTGER4GRM2 | |
| SCHEMBL20150353 | 0.87 | PTGER4 (0.37) | CYP11B1CYP11B2CHEK1PTGER4TNKS2 | |
| SCHEMBL20655088 | 0.87 | — | — | |
| SCHEMBL20114573 | 0.86 | CASP3 (0.38) | CRHR1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421746-B2 | Organic molecules, especially for use in organic optoelectronic devices | CYNORA GMBH (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, EPCAM, F12 | CYP11B1 1765/4885CYP11B2 1259/4885CHEK1 2795/4885 |
| US-10421746-B2 | Organic molecules, especially for use in organic optoelectronic devices | OR10J3, EPCAM, F12 | CYP11B1 1765/4885CYP11B2 1259/4885CHEK1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.